Phenelzine efficacy in refractory social anxiety disorder: A case series

Nordic Journal of Psychiatry

Volumn 57, Issue 4, 2003, Pages 313-315

  Aarre, Trond F ^a  

^a Nordfjord Psychiatric Centre   (Norway)

Author keywords

Phenelzine; Social anxiety disorder; Treatment resistant

Indexed keywords

ALPRAZOLAM; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; ENZYME INHIBITOR; LITHIUM; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; PHENELZINE; PINDOLOL; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; BODY WEIGHT DISORDER; CLINICAL ARTICLE; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPOTENSION; MAINTENANCE THERAPY; MALE; RATING SCALE; REFLEX DISORDER; SCHOOL; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; TABLET FORMULATION; TENDON REFLEX; TREATMENT FAILURE; URINARY HESITANCY; WORK; XEROSTOMIA;

ADULT; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; PHENELZINE; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 0042326758     PISSN: 08039488     EISSN: None     Source Type: Journal    
DOI: 10.1080/08039480310002110     Document Type: Article

References (14)

1. Kringlen E, Torgersen S, Cramer V. A Norwegian psychiatric epidemiological study. Am J Psychiatry 2001;158:1091-8.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
3. Chartier MJ, Hazen AL, Stein MB. Lifetime patterns of social phobia: a retrospective study of the course of social phobia in a non-clinical population. Depress Anxiety 1998;7:113-21.
4. Degonda M, Angst J. The Zurich study XX: social phobia and agoraphobia. Eur Arch Psychiatry Clin Neurosci 1993;243:95-102.
5. Goldenberg IM, White K, Yonkers K, Reich J, Warshaw MG, Goisman RM, et al. The infrequency of "pure culture" diagnoses among the anxiety disorders. J Clin Psychiatry 1996;57:528-33.
6. Merikangas KR, Angst J. Comorbidity and social phobia: evidence from clinical, epidemiological, and genetic studies. Eur Arch Psychiatry Clin Neurosci 1995;244:297-303.
7. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DN, Bobes J, Beidel DC, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry ;59 Suppl 1998;17:54-60.
8. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, et al. Cognitive-behavioral and pharmacological treatments of social phobia. Arch Gen Psychiatry 1991;48:938-45.
9. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, et al. Cognitive behavioral group therapy vs. phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55:1133-41.
10. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine versus atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
11. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-60.
12. Guy W. ECDEU Assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education and Welfare; 1976.
13. Derogatis RL, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist: a self-report symptom inventory. Behav Sci 1974;19:1-15.
14. Liebowitz MR. Social phobia. In: Klein DF, editor. Modern problems in pharmacopsychiatry, anxiety. Basel: Karger; 1987.